LONDON: Pakistan is on the verge of a major medical breakthrough as preparations are underway to introduce the country’s first-ever gene therapy for the treatment of thalassemia, a life-threatening blood disorder affecting thousands of patients nationwide. The revolutionary treatment is expected to significantly reduce, and potentially eliminate, the lifelong dependence on regular blood transfusions.
Renowned UK-based Pakistani gene therapist Dr. Sher Bahadur Anjum said that gene therapy offers a long-term solution by addressing the disease at its genetic root. He explained that following successful treatment, many thalassemia patients may no longer require frequent blood transfusions and can lead healthy, normal lives.
Dr. Anjum described the development as a milestone for Pakistan’s healthcare system and a turning point for families burdened by the physical, emotional, and financial challenges of thalassemia. He emphasized that gene therapy represents not just another treatment option but a transformative approach with lasting impact.
In recognition of his outstanding humanitarian services and contributions to advancing thalassemia care, a special award ceremony is being organized in London. The event is being jointly hosted by the Professional Relief Organization (PRO) and the Amina Bashir Memorial Thalassemia Trust (ABMT).
Organizers said Dr. Sher Bahadur Anjum will be honored for his dedication, innovation, and sustained efforts to make advanced gene therapy accessible to Pakistani patients.
Health experts believe the introduction of gene therapy marks a historic step forward for Pakistan’s medical sector and offers renewed hope for thousands of children and families affected by thalassemia, paving the way for a healthier future.
